Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 0.56 |
| ▸ | CES1 | P23141 | 8/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16139998 | 0.86 | FAAH (0.48) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL14410294 | 0.79 | CA1 (0.41) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL11983875 | 0.78 | FAAH (0.42) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7368811 | 0.77 | LMNA (0.49) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1191303 | 0.74 | PTPN1 (0.38) | MEN1KMT2ABLMCA1 | |
| SCHEMBL11606311 | 0.74 | CA1 (0.41) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL14279367 | 0.74 | FAAH (0.57) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7242957 | 0.74 | FAAH (0.47) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL809819 | 0.73 | FAAH (0.86) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL23776844 | 0.73 | GABRP (0.54) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20210147470-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2013036835-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147470-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | FAAH 1396/4885CES1 1084/4885CES2 762/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | FAAH 854/4885CES1 915/4885CES2 348/4885 |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | FAAH 854/4885CES1 915/4885CES2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.